387 related articles for article (PubMed ID: 15514380)
1. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
[TBL] [Abstract][Full Text] [Related]
3. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
5. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
[TBL] [Abstract][Full Text] [Related]
6. [Current results of cooperative AML therapy studies in children: BFM-78 and 83].
Creutzig U; Ritter J; Budde M; Riehm H; Henze G; Lampert F; Gerein V; Müller-Weihrich S; Niethammer D; Spaar HJ
Klin Padiatr; 1986; 198(3):183-90. PubMed ID: 3523024
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
9. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Lehrnbecher T; Varwig D; Kaiser J; Reinhardt D; Klingebiel T; Creutzig U
Leukemia; 2004 Jan; 18(1):72-7. PubMed ID: 14586478
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
11. [Improved results in the treatment of acute myeloid leukemia - Results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87].
Steinbach D; Dörffel W; Eggers G; Holfeld E; Kluba U; Krause I; Lauterbach I; Reiss T; Rieske K; Scharfe V; Schumacher R; Weigel H; Weinmann G; Zintl F; Hermann J
Klin Padiatr; 2001; 213(4):162-8. PubMed ID: 11528549
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
13. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
14. [Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Vormoor J; Ritter J; Creutzig U; Schellong G
Klin Padiatr; 1989; 201(4):227-32. PubMed ID: 2674529
[TBL] [Abstract][Full Text] [Related]
15. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Ritter J; Creutzig U; Schellong G
Leukemia; 1992; 6 Suppl 2():59-62. PubMed ID: 1578943
[TBL] [Abstract][Full Text] [Related]
16. Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
Vormoor J; Ritter J; Creutzig U; Boos J; Heyen P; Ludwig WD; Harbott J; Löffler H; Schellong G
Br J Cancer Suppl; 1992 Aug; 18():S63-7. PubMed ID: 1503929
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of eosinophilia in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Creutzig U; Ritter J; Niederbiermann-Koczy G; Harbott J; Schellong G
Klin Padiatr; 1989; 201(4):220-6. PubMed ID: 2674528
[TBL] [Abstract][Full Text] [Related]
18. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
Godwin J
J Natl Cancer Inst Monogr; 1995; (19):31-5. PubMed ID: 7577202
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Okamoto T; Kanamaru A; Shimazaki C; Motoji T; Takemoto Y; Takahashi M; Fukushima T; Takeshita A; Kusumoto GS; Kishimoto Y; Yorimitsu S; Tsukuda K; Uike N; Arima N; Ohno R
Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
[TBL] [Abstract][Full Text] [Related]
20. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
